Omkar Pharmachem Ltd.

As of June 30, 2026, Omkar Pharmachem Ltd. carries a market capitalization of 200.20M, placing it among publicly traded companies globally. Its enterprise value stands at 200.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Omkar Pharmachem Ltd. has 10.10M shares outstanding.

As of June 30, 2026, Omkar Pharmachem Ltd. trades at a trailing price-to-earnings ratio of 234.57.

As of June 30, 2026, Omkar Pharmachem Ltd. trades at an EV/EBITDA multiple of 174.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 179.07 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 200.20M versus a market cap of 200.20M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Omkar Pharmachem Ltd. recorded 319,000.00 in income tax expense. That works out to an effective tax rate of 27.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.17M, leaving 852,000.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Omkar Pharmachem Ltd.'s stock has declined approximately 74.48% over the past 52 weeks. The 50-day moving average sits at 10.77, while the 200-day moving average is 20.29.

Over the twelve months ended June 30, 2026, Omkar Pharmachem Ltd. generated - - in revenue and converted that into 852,000.00 in net income, yielding earnings per share of 0.08. EBITDA reached 1.15M, while operating income came in at 1.12M.